Volume 9, Issue 2 (Vol.9 No.2 Jul 2020)                   rbmb.net 2020, 9(2): 147-155 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Moghazy H, Mahmoud A, ElBadre H, Abdel Aziz H O. Protective Effect of Oxytocin Against Bone Loss in a Female Rat Model of Osteoporosis. rbmb.net 2020; 9 (2) :147-155
URL: http://rbmb.net/article-1-485-en.html
Medical Biochemistry Department, Faculty of Medicine, Sohag University, Egypt
Abstract:   (3273 Views)
Background: Introduction: Oxytocin (OT) has been proposed to assist in the regulation of bone remodeling and to exert an antiosteoporotic effect. We evaluated the possible protective effect of OT against bone degeneration in ovariectomized (OVX) rats.

Methods: The study was performed on three groups of adult female rats; group I was subjected to sham operation, group II was subjected to ovariectomy, and group III was subjected to ovariectomy and intraperitoneal injection with OT for eight successive weeks. At the end of the study, bone mass density (BMD) was measured; then the rats were euthanized and their blood and bone tissues were examined.

Results: The group II rats had significantly less BMD and greater serum bone-specific alkaline phosphatase (bALP), osteocalcin (OC), and tartrate-resistant acid phosphatase (TRAP) levels than the group I rats. Furthermore, group II rats had fewer osteocytes and osteoblasts, and less OPG/RANKL mRNA expression than group I rats. The groups I and III and rats showed no significant differences in BMD, bALP, OC, TRAP, OPG/RANKL mRNA expression, or osteocyte and osteoblast numbers.

Conclusions: Oxytocin may have an antiosteoporotic effect in OVX rats.
Full-Text [PDF 218 kb]   (1614 Downloads)    
Type of Article: Original Article | Subject: Cell Biology
Received: 2020/04/11 | Accepted: 2020/04/27 | Published: 2020/10/7

References
1. Camara CE, Linyuan Z, Dong YU, Yaowu Z, Nianhong Y. Serum osteocalcin levels and bone mineral density in ovariectomized rats. International Journal of Innovation and Scientific Research. 2014;5(1): 1-8.
2. Mukaiyama K, Kamimura M, Uchiyama S, Ikegami S, Nakamura Y, Kato H. Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover. Aging Clin Exp Res. 2015;27(4):413-8. [DOI:10.1007/s40520-014-0296-x] [PMID]
3. Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res. 2017;5:18. [DOI:10.1186/s40364-017-0097-4] [PMID] [PMCID]
4. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. World Heart Federation; World Stroke Organization. 2011
5. Parra-Torres AY, Valdes-Flores M, Orozco L, Velazquez-Cruz R. Molecular Aspects of Bone Remodeling. Topics in Osteoporosis. 2013.
6. Schorr M, Marengi DA, Pulumo RL, Yu E, Eddy KT, Klibanski A, et al. Oxytocin and Its Relationship to Body Composition, Bone Mineral Density, and Hip Geometry Across the Weight Spectrum. J Clin Endocrinol Metab. 2017;102(8):2814-2824. [DOI:10.1210/jc.2016-3963] [PMID] [PMCID]
7. Colaianni G, Tamma R, Di Benedetto A, Yuen T, Sun L, Zaidi M, et al. The oxytocin-bone axis. J Neuroendocrinol. 2014;26(2): 53-7. [DOI:10.1111/jne.12120] [PMID] [PMCID]
8. Colaianni G, Sun L, Di Benedetto A, Tamma R, Zhu LL, Cao J, et al. Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton. J Biol Chem. 2012;287(34): 29159-67. [DOI:10.1074/jbc.M112.365049] [PMID] [PMCID]
9. Weigt C, Hertrampf T, Zoth N, Fritzemeier KH, Diel P. Impact of estradiol. ER subtype specific agonists and genistein on energy homeostasis in a rat model of nutrition induced obesity. Mol Cell Endocrinol. 2012;351(2): 227-38. [DOI:10.1016/j.mce.2011.12.013] [PMID]
10. Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ., 2007;335(7613):239. [DOI:10.1136/bmj.39266.425069.AD] [PMID] [PMCID]
11. Colaianni G, Sun L, Zaidi M, Zallone A. Oxytocin and bone. Am J Physiol Regul Integr Comp Physiol. 2014;307(8):R970-7. [DOI:10.1152/ajpregu.00040.2014] [PMID] [PMCID]
12. Alessandri N, Piccioni M, Isabelli V, Alessandri G, Di Matteo A, Padovani D, Rondoni G, Camardella B, Parlapiano C. Morphological and functional changes of cardiovascular system in postmenopausal women. Eur Rev Med Pharmacol Sci. 2007;11(2):107-117.
13. Beranger G.E, Pisani DF, Castel J, Djedaini M, Battaglia S, Amiaud J, Boukhechba F, Ailhaud G, Michiels JF, Heymann D, Luquet S. Oxytocin reverses ovariectomy-induced osteopenia and body fat gain. Endocrinology. 2014;155(4):1340-1352. [DOI:10.1210/en.2013-1688] [PMID]
14. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007. 9(Suppl1). [DOI:10.1186/ar2165] [PMID] [PMCID]
15. Xu C. RANKL-RANK signaling regulates osteoblast differentiation and bone formation. Bone Res. 2018;6:35. [DOI:10.1038/s41413-018-0040-9] [PMID] [PMCID]
16. Fallahnezhad S, Piryaei A, Darbandi H, Amini A, Ghoreishi SK, Jalalifirouzkouhi R, et al. Effect of low-level laser therapy and oxytocin on osteoporotic bone marrow-derived mesenchymal stem cells. J Cell Biochem. 2018;119(1): 983-997. [DOI:10.1002/jcb.26265] [PMID]
17. Khajuria DK, Razdan R, Mahapatra DR. Description of a new method of ovariectomy in female rats. Rev Bras Reumatol. 2012;52(3):462-70. [DOI:10.1590/S0482-50042012000300016]
18. Beranger GE, Djedaini M, Battaglia S, Roux CH, Scheideler M, Heymann D, Amri EZ, Pisani DF. Oxytocin reverses osteoporosis in a sex-dependent manner. Front Endocrinol (Lausanne). 2015;6:81. [DOI:10.3389/fendo.2015.00081] [PMID] [PMCID]
19. Levin V. A., Jiang X., Kagan. Estrogen therapy for osteoporosis in the modern era. Osteoporos Int. 2018;29:1049-1055. [DOI:10.1007/s00198-018-4414-z] [PMID]
20. Li CW, Liang B, Shi XL, Wang H. Opg/Rankl mRNA dynamic expression in the bone tissue of ovariectomized rats with osteoporosis. Genet Mol Res. 14(3):9215-9224. [DOI:10.4238/2015.August.10.1] [PMID]
21. Kalaiselvi VS, Prabhu K, Ramesh M. Venkatesan V. Association of Serum Osteocalcin with Bone Mineral Density in Postmenopausal Women. J Clin Diagn Res. 2013;7(5):814-816.
22. Grigoryan AV, Dimitrova AA, Kostov KG, Russeva AL, Atanasova MA, Blagev AB, et al. Changes of serum concentrations of alkaline phosphatase and metalloproteinase-9 in an ovariectomized wistar rat model of osteoporosis. J Biomed Clin Res. 2017;10(1):32-36. [DOI:10.1515/jbcr-2017-0006]
23. Rogers A, Saleh G, Hannon RA, Greenfeld D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab. 2002;87(10):4470-5. [DOI:10.1210/jc.2002-020396] [PMID]
24. Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, et al. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. Endocrinology. 2014;155(12):4785-97. [DOI:10.1210/en.2013-1905] [PMID]
25. Li L, Chen X, Lv S, Dong M, Zhang L, Tu J, et al. Influence of Exercise on Bone Remodeling-Related Hormones and Cytokines in Ovariectomized Rats: A Model of Postmenopausal Osteoporosis. PLoS One. 2014;9(11):e112845. [DOI:10.1371/journal.pone.0112845] [PMID] [PMCID]
26. Feresin RG, Johnson S A, Elam ML, Kim JS, Khalil DA, Lucas EA, et al. Effects of Vitamin e on Bone Biomechanical and Histomorphometric Parameters in Ovariectomized Rats. J Osteoporosis. 2013:825985. [DOI:10.1155/2013/825985] [PMID] [PMCID]
27. Yamagishi T, Kawashima H, Ogose A, Ariizumi T, Oike N, Sasaki T, et al. Expression Profiling of Receptor-Activator of Nuclear Factor Kappa B Ligand in Soft Tissue Tumors. Tohoku J Exp Med. 2019;248(2):87-97. [DOI:10.1620/tjem.248.87] [PMID]
28. Tulay Okman-Kilic. Estrogen Deficiency and Osteoporosis. Advances in Osteoporosis. 2015 [DOI:10.5772/59407]
29. Perilli E, Le V, Ma B, Salmon P, Reynolds K, Fazzalari NL Detecting early bone changes using in vivo micro-CT in ovariectomized, zoledronic acid-treated, and sham-operated rats. Osteoporos Int. 2010;21(8):1371-82. [DOI:10.1007/s00198-009-1082-z] [PMID]
30. Santos LF, Singulani MP, Stringhetta-Garcia CT, Oliveira SHP, Chaves-Neto AH, Dornelles RCM. Oxytocin effects on osteoblastic differentiation of Bone Marrow Mesenchymal Stem Cells from adult and aging female wistar rats. Exp Gerontol. 2018;113:58-63. [DOI:10.1016/j.exger.2018.09.023] [PMID]
31. Tamma R, Colaianni G, Zhu LL, DiBenedetto A, Greco G, Montemurro G, et al. Oxytocin is an anabolic bone hormone. Proc Natl Acad Sci U S A. 2009;106(17):7149-54. [DOI:10.1073/pnas.0901890106] [PMID] [PMCID]
32. Kim SH, MacIntyre DA, Firmino Da Silva M, Andrew M Blanks 2, Yun S Lee 1, Steven Thornton et al. Oxytocin activates NF-κB-mediated inflammatory pathways in human gestational tissues. Mol Cell Endocrinol. 2015;403:64-77. [DOI:10.1016/j.mce.2014.11.008] [PMID]
33. Jin B, Du Y, Zhang F, Zhang K, Wang L, Cui L. Carbetocin for the prevention of postpartum hemorrhage: a systematic review and meta-analysis of randomized controlled trials. J Matern Fetal Neonatal Med 2016;29(3):400-7. [DOI:10.3109/14767058.2014.1002394] [PMID]
34. Cavallaro G, Maniscalco L, Campisi M, Schillaci D, Giammona G. Synthesis, characterization and in vitro cytotoxicity studies of a macromolecular conjugate of paclitaxel bearing oxytocin as targeting moiety. European Journal of Pharmaceutics and Biopharmaceutics. 2007;66(2):182-192. [DOI:10.1016/j.ejpb.2006.10.013] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb